c-Raf in KRas Mutant Cancers: A Moving Target

Cancer Cell. 2018 Feb 12;33(2):158-159. doi: 10.1016/j.ccell.2018.01.017.

Abstract

Therapies for KRas cancers remain a major clinical need. In the current issue of Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf as a prime target for these cancers. c-Raf ablation caused regression of advanced KRasG12V/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.

Publication types

  • Comment

MeSH terms

  • Cell Line, Tumor
  • Genes, ras*
  • Humans
  • Mutation
  • Neoplasms / genetics
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins p21(ras)*

Substances

  • KRAS protein, human
  • Proto-Oncogene Proteins
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins p21(ras)